Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
NCT00970996
Completed
The goal of this clinical research study is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given in combination with cisplatin, Temodar (temozolomide), interferon alfa-2b, and interleukin-2 (IL-2) to patients with metastatic melanoma. Primary Objective: * The primary objective of the Phase I is to determine the toxicity, safety and the maximum tolerated dose maximum tolerated dose of Abraxane in combination with Cisplatin, Temozolomide, interleukin-2 and interferon a2b in... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/31/2012
Locations: U.T. M.D. Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Register for Updates
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
NCT00373256
Completed
To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2012
Locations: Pfizer Investigational Site, Amarillo, Texas +28 locations
Conditions: Breast Neoplasms
Register for Updates
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00294762
Completed
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients with EGFR overexpression and/or EGFR amplification.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2012
Locations: University of Texas M.D. Anderson Cancer Center, Houston, Texas
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
NCT00038168
Completed
Phase I: The goal of this clinical research study is to find the highest dose of estramustine phosphate administered intravenously in combination with a fixed dose of Taxol (paclitaxel) that can be given safely to participants with prostate cancer who have failed to further benefit from hormone treatment. Phase II: The goal of this clinical research study is to find out if the combination of the drugs estramustine phosphate and paclitaxel will shrink or control prostate cancer that has not resp... Read More
Gender:
MALE
Ages:
All
Trial Updated:
07/31/2012
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer
NCT00002837
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose combination chemotherapy and peripheral stem cell transplantation in treating patients with recurrent or metastatic breast cancer.
Gender:
ALL
Ages:
Between 15 years and 60 years
Trial Updated:
07/27/2012
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
NCT00003084
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/27/2012
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer
NCT00006081
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining bryostatin 1 and paclitaxel in treating patients who have unresectable locally advanced or metastatic stomach cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/27/2012
Locations: CCOP - M.D. Anderson Research Base, Houston, Texas +1 locations
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement
NCT00508326
Completed
The goal of this clinical research study is find the highest tolerated dose of paclitaxel that can be given directly into the liver of patients with advanced cancer involving the liver. Researchers also want to collect descriptive information on any effects the drug may have on tumor tissue.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
07/27/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer
Register for Updates
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
NCT00512096
Completed
Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
Gender:
MALE
Ages:
14 years and above
Trial Updated:
07/27/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Penile Cancer
Register for Updates
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
NCT00038402
Completed
The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/19/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
NCT00050960
Completed
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2012
Locations: Texas Oncology, P.A., Arlington, Texas +14 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer
NCT00057928
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin is more effective when combined with paclitaxel or gemcitabine in treating cervical cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with paclitaxel to that of cisplatin combined with gemcitabine in treating women who have recurrent, persi... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
06/11/2012
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +9 locations
Conditions: Cervical Cancer
Register for Updates